Is the 2nd generation DES an alternative to surgery in multivessel coronary disease?

The benefits of 2nd generation drug-eluting stents (DES) are being compared with Coronary artery bypass graft surgery (CABG), looking to achieve a safe, effective, less invasive and as complete as possible revascularization. As background of SYNTAX, the stent thrombosis (ST) with Taxus, reached 25% of the events in the group of intervention (PCI), so that the appearance of the 2nd generation DES with greater safety and reduced ischemic events gave new hope to this therapy.

 

The BEST is a randomized, non-inferiority study, which compared 448 patients assigned to PCI versus 442 assigned to CABG. Patients with at least two severe lesions (>50%) were included in different vessels. We excluded patients with severe LMCA disease.

 

The primary endpoint was a composite of death, myocardial infarction (MI) or revascularization of treated vessel at 2 years of randomization. Secondary endpoints were one composed of safety (death, MI, stroke, or any new revascularization) plus the components of the primary individualized, intrastent thrombosis and greater or fatal bleeding.

 

The primary endpoint at 2 years was similar (PCI 11% versus CABG 7.9%) but at 4.6 years occurred more frequently in PCI (PCI 15.3% versus CABG 10.6%, HR 1.47; CI 95%, 1.01 to 2.13; p = 0.04) and more significantly in diabetics (PCI 19.2% versus CABG 9.1%, p = 0.007). The composite secondary endpoint was PCI 19.9%.

 

Original title: Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease. The BEST Trial. 
Reference: Seung-Jung Park, M.D., Ph.D., Jung-Min Ahn, M.D., Young-Hak Kim, M.D. et al. N Engl J Med 2015; 372:1204-1212 March 26, 2015.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...